Welcome to our dedicated page for Pulmonx Corporation news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx Corporation stock.
Pulmonx Corporation (Nasdaq: LUNG) is a leading medical technology company dedicated to transforming the treatment of severe lung diseases. The company's primary focus is on developing life-changing, minimally invasive technologies to enhance the lives of patients suffering from emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). Pulmonx's flagship product, the Zephyr Endobronchial Valve (EBV), offers a non-surgical treatment option to reduce the volume of diseased lung tissue, thereby improving breathing and increasing patients' activity levels. This innovative approach provides a viable alternative to lung volume reduction surgery and lung transplantation, which have significant limitations and risks.
Pulmonx also offers the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which work in tandem with the Zephyr Valve to optimize patient selection and treatment outcomes. These technologies are pivotal in managing advanced emphysema and are commercially available in over 25 countries.
In recent financial updates, Pulmonx reported robust growth, with total worldwide revenue reaching $17.2 million in Q2 2023, marking a 23% increase compared to the same period in 2022. U.S. revenue alone saw a 28% rise, highlighting the strong domestic market traction. The company's ongoing commercial success and adoption of Zephyr Valve procedures are driving this growth.
Pulmonx's fiscal health remains strong, with a gross profit of $12.7 million in Q2 2023 and a gross margin of 74%. Operating expenses rose to $29.2 million, mainly due to increased clinical and development costs associated with the AeriSeal program, alongside higher selling, legal, and stock-based compensation expenses. Despite a net loss of $16.2 million for the quarter, the company maintains significant cash reserves, totaling $147.6 million as of June 30, 2023.
Looking ahead, Pulmonx has raised its 2023 revenue guidance to $64-$66 million, reflecting an expected growth rate of 19%-23% over the previous year. Operating expenses for the year are projected to be between $112 million and $114 million. The company remains committed to expanding its global market reach and meeting the substantial unmet clinical needs of patients with severe emphysema.
For investors and stakeholders, Pulmonx represents a dynamic and promising entity in the medtech space, continually striving to enhance patient outcomes through groundbreaking innovations in pulmonary care.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will participate in two investor conferences in New York. Management will hold a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 8:00 AM ET, with a live webcast available on their website. Additionally, they will engage in investor meetings at the Canaccord Genuity MedTech Forum on November 17, 2022. The company’s Zephyr Valve, used for treating emphysema/COPD, has gained FDA approval and is available in over 25 countries.
Pulmonx Corporation (Nasdaq: LUNG) reported Q3 2022 revenues of $13.5 million, up 2% year-over-year, with U.S. revenue of $8.4 million reflecting a strong 22% growth. The gross margin improved to 75% from 73% a year prior, driven by production efficiencies. However, international revenue fell by 20%.
Net loss widened to $14.2 million or $0.38 per share. The company lowered its full-year 2022 revenue guidance to $51.5 million to $52.5 million from a prior estimate of $55 million to $60 million. Despite challenges, Pulmonx aims to expand its market presence.
Pulmonx Corporation (Nasdaq: LUNG) will announce its third-quarter 2022 financial results on November 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Pulmonx specializes in minimally invasive treatments for lung disease, particularly through its FDA-approved Zephyr® Endobronchial Valve, which has been used in over 25,000 patients globally. Interested parties are encouraged to register online for the call, which will also be available via live and archived webcast.
Pulmonx Corporation (NASDAQ: LUNG) reported promising interim results from the CONVERT clinical trial presented at the 2022 European Respiratory Society (ERS) International Conference. The trial demonstrated that the AeriSeal System successfully closed collateral air channels in 78% of patients with severe COPD/emphysema, making them eligible for Zephyr Endobronchial Valves. Notable improvements were observed in lung function (FEV1 increase of 19.7%), quality of life (SGRQ score decrease of 15.1), and exercise capacity (Six-Minute Walk Distance increase of 77.2 meters).
Pulmonx Corporation (NASDAQ: LUNG) has announced promising interim results from the CONVERT Study presented at the 2022 European Respiratory Society Conference. The study indicates that the AeriSeal System successfully converted collateral ventilation status in 78% of patients, enabling them to receive Zephyr Valves treatment. The trial demonstrated a mean Target Lobe Volume Reduction of over 1 liter, improving lung function by 19.7%, quality of life, and exercise capacity. No serious adverse reactions were noted in recent studies, marking a significant advancement in the treatment of severe COPD.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, announced its participation in two upcoming investor conferences. The company will speak at the Wells Fargo Healthcare Conference in Boston on September 7, 2022, at 6:10 AM PT/9:10 AM ET, and the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 13, 2022, at 1:40 PM PT/4:40 PM ET. A live webcast of the presentations will be accessible on Pulmonx’s investor website.
Pulmonx reported strong Q2 2022 results with worldwide revenue reaching $14.0 million, a 14% increase year-over-year. U.S. revenue surged 31% to $8.6 million, driven by Zephyr Valve procedures. Gross margin improved to 75%, up from 74% in Q2 2021. However, operating expenses rose 14% to $24.8 million, contributing to a net loss of $14.6 million or $0.40 per share. Pulmonx maintains its full-year revenue guidance of $55-$60 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible on the company's Investors page. Pulmonx is known for its Zephyr® Endobronchial Valve, which has treated over 25,000 patients worldwide, and received FDA premarket approval as a breakthrough device.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q2 2022 financial results on August 2, 2022, after market close. A conference call will be held at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. Pulmonx is a leader in minimally invasive treatments for lung disease, notably through its FDA-approved Zephyr® Endobronchial Valve, which is available in over 25 countries. The company has treated more than 25,000 patients with over 100,000 valves used.
Pulmonx Corporation (LUNG) reported Q1 2022 financial results, highlighting a 17% increase in worldwide revenue to $10.8 million compared to Q1 2021. U.S. revenue surged 40% to $6.0 million, driven by growth in Zephyr Valve procedures. Gross margin improved to 75%, up from 72%, despite operating expenses rising 24% to $23.8 million. The net loss for the quarter was $15.8 million, or $0.43 per share. Pulmonx maintains its 2022 revenue outlook of $55 million to $60 million amidst ongoing investments and challenges from COVID and foreign exchange rates.
FAQ
What is the current stock price of Pulmonx Corporation (LUNG)?
What is the market cap of Pulmonx Corporation (LUNG)?
What is Pulmonx Corporation's primary focus?
What products does Pulmonx offer?
How does the Zephyr Endobronchial Valve work?
What recent financial achievements has Pulmonx reported?
What is Pulmonx's financial outlook for 2023?
In which markets are Pulmonx's products commercially available?
What are the key benefits of the Zephyr Valve treatment?
How does Pulmonx support its products' adoption in the medical community?
Who is the current interim CFO of Pulmonx Corporation?
Where can I find more information about Pulmonx Corporation?
